UPB Upstream Bio
Price Chart
Executive Summary
Upstream Bio reported Q1 2026 EPS of -$0.79, missing consensus of -$0.75 by 5.3%, with net loss widening to $40.6M from $27.3M a year ago. The company is advancing Phase 3 plans for verekitug in severe asthma and CRSwNP with FDA meetings expected mid-2026 and Phase 3 initiations in Q1 2027, while capping enrollment in the COPD trial with data now expected in H2 2027. Cash of $294.6M funds operations through 2027, but the EPS miss and widening losses weigh on near-term sentiment.
Actionable Insight
The EPS miss and widening losses are negative, but the stock's movement will hinge on Phase 3 catalyst timing and any data readouts at upcoming conferences (ATS May 15-20). Monitor for FDA meeting outcomes mid-2026 and potential partnership or financing needs given cash burn trajectory.
Key Facts
- Q1 2026 EPS -$0.79 vs consensus -$0.75 (5.3% miss)
- Net loss widened to $40.6M from $27.3M in Q1 2025
- Cash, cash equivalents and short-term investments $294.6M as of March 31, 2026
- Phase 2 VENTURE COPD trial enrollment capped; data now expected H2 2027 (delayed from prior timeline)
- Phase 3 initiations in severe asthma and CRSwNP expected Q1 2027
- Research and development expenses increased 42% to $36.6M
Financial Impact
EPS miss of $0.04 per share; net loss increased $13.3M YoY
Risk Factors
- Clinical trial failure in Phase 3 severe asthma or CRSwNP
- Cash burn rate may require dilutive financing before Phase 3 data
- COPD trial delay to H2 2027 pushes back a key catalyst
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293845 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 18, 2026
23d ago
|
Press Release
| $8.51 $8.21 | ▼ −3.53% | ▼ −5.14% | $6.43 (−24.44%) |
|
May 13, 2026
28d ago
|
Press Release
| $9.36 $8.03 | ▲ +14.21% | ▲ +13.05% | $6.43 (+31.30%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $9.99 $9.30 | ▼ −6.91% | ▼ −7.46% | $6.43 (−35.64%) |
|
Mar 26, 2026
10w ago
|
424B5
| $8.67 $9.72 | ▼ −12.11% | ▼ −8.25% | $6.43 (+25.84%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $9.79 $9.50 | ▼ −2.96% | ▼ −4.60% | $6.43 (−34.32%) |
|
Mar 16, 2026
12w ago
|
Insider Cluster
| $9.61 $8.45 | ▼ −12.07% | ▼ −10.03% | $6.43 (−33.09%) |
|
Mar 1, 2026
14w ago
|
Press Release
| $7.70 $8.06 | ▲ +4.68% | ▲ +5.88% | $6.43 (−16.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access